Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
Research-based charities are taking on an ever-growing role in frontline clinical research, and Myeloma UK has just launched a ‘stratified medicine’ trial aimed at helping high risk patient
